

K073386

JUL 30 2008

Pain Management Technologies, Inc.  
510(k) submission  
J-Stim 1000™

**510(k) Summary of Safety and Effectiveness**  
(As described in 21 CFR 807.92)

**Date Prepared:** 11-1-07  
**Trade Name/Device:** J-Stim 1000™

**Applicant Information:** Pain Management Technologies, Inc.  
1340 Home Ave. Bldg. A  
Akron, OH 44310  
800-239-7880 (phone)  
888-304-5454 (fax)  
Contact: Joshua Lefkovitz  
  
Registration No. 1528161

**Device Generic Name:** TENS (Transcutaneous Electrical Nerve Stimulator)

**Classification:** Class II (21CFR 882.1320)  
Classification Name: Transcutaneous electrical nerve  
stimulator for pain relief  
Product Code: NYN  
Regulation number 21 CFR 882.5890

**Predicate Devices:** The Bionicare Stimulator, Model Bio 1000 - K030332  
and the K052625

**Device Description:**

The J-Stim 1000 consists of electrodes, the lead wires, and the signal generator. The Stimulator is portable, battery operated and rechargeable. The Lead wires connect the electrodes to the stimulator. These electrodes complete an electrical circuit allowing current to flow. The stimulator produces a pulsed electrical signal through the lead wires and electrodes at the treatment site.

**Statement of intended use:**

The J-Stim 1000 is indicated for use as an adjunctive therapy in reducing the level of pain and symptoms associated with Osteoarthritis of the knee and Rheumatoid Arthritis of the Hand.

**Summary of technology of the J-Stim vrs. the predicate Bionicare device:**

The J-Stim 1000 and the Bionicare 1000 generate the exact same electrical output. They produce the same frequency. The same wave form as a monophasic spiked shaped pulse. The same voltage output range which is 0-12 volts peak, as well as the same dual channel output performance. Pulse widths and max output values are identical as well. The J-Stim 1000 utilizes an LCD screen to display the settings



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Pain Management Technologies  
% Mr. Joshua Lefkovitz  
President  
1340 Home Avenue, Building A  
Akron, Ohio 44310

JUL 30 2008

Re: K073386  
Trade/Device Name: J-Stim 1000™  
Regulation Number: 21 CFR 882.5890  
Regulation Name: Transcutaneous electrical nerve stimulator for pain relief.  
Regulatory Class: Class II  
Product Code: NYN  
Dated: June 6, 2008  
Received: June 13, 2008

Dear Mr. Lefkovitz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address <http://www.fda.gov/cdrh/industry/support/index.html>

Sincerely yours,



Mark N. Melkerson  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

Pain Management Technologies, Inc.  
510(k) submission  
J-Stim 1000™

### Indications for Use Statement

510k Number: K073386

Device Name: J-Stim 1000™

#### Indication for Use:

The J-Stim 1000™ external, non-invasive, non-narcotic, electrotherapy system is indicated for use as an adjunctive therapy in reducing the level of pain and symptoms associated with osteoarthritis of the knee and for overall improvement of the knee.

The J-Stim 1000™ is also indicated for use as an adjunctive therapy in reducing the level of pain, and stiffness associated with pain, from rheumatoid arthritis of the hand.

These devices are to be used or sold only under the direct supervision or order of a licensed practitioner. A prescription is required to obtain this product. The product can be used in the home or clinic by all patients in need.

Prescription Use ☒  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use ☐  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE OR ON ANOTHER PAGE  
OF NEEDED)

**Division of General, Restorative,  
and Neurological Devices**

510(k) Number K073386